World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
106
Citations
71229
World Ranking
6363
National Ranking
178

Research.com Recognitions

  • 2015 - Fellow of the Australian Academy of Health and Medical Science
  • 1986 - Fellow of John Simon Guggenheim Memorial Foundation

Overview

Timothy P. Hughes is affiliated with the South Australian Health and Medical Research Institute in Australia. Their body of work primarily focuses on medical research with a specialization in hematology within the broader field of medicine.

The scientist's research spans key topics including:

  • Chronic Myeloid Leukemia Treatments
  • Chronic Lymphocytic Leukemia Research
  • Eosinophilic Disorders and Syndromes
  • Acute Myeloid Leukemia Research
  • Acute Lymphoblastic Leukemia Research
  • HER2/EGFR in Cancer Research
  • Lung Cancer Treatments and Mutations

Their most frequent publication venues reflect a focus on hematology and oncology-related fields and include:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Leukemia
  • HemaSphere
  • British Journal of Haematology

Timothy P. Hughes has contributed to a number of peer-reviewed papers, some notable recent publications are:

  • "European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia" (2020, Leukemia)
  • "Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis" (2021, Leukemia)
  • "A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs" (2021, Blood)
  • "Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL" (2023, Leukemia)
  • "Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia" (2021, Nature Communications)

Frequent collaborators of the scientist include:

  • Jorge E. Cortés
  • Andreas Hochhaus
  • David T Yeung
  • Delphine Réa
  • Michael J. Mauro

Timothy P. Hughes's research covers subfields such as:

  • Hematology
  • Genetics
  • Rheumatology
  • Oncology
  • Public Health, Environmental and Occupational Health

Awards received by the scientist include:

  • Fellow of the Australian Academy of Health and Medical Science (2015)
  • Fellow of John Simon Guggenheim Memorial Foundation (1986)

Best Publications

  • Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

    Stephen G. O'Brien;François Guilhot;Richard A. Larson;Insa Gathmann

  • Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

    Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann

  • European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

    Michele Baccarani;Michael W. Deininger;Gianantonio Rosti;Andreas Hochhaus

  • Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

    Giuseppe Saglio;Dong-Wook Kim;Surapol Issaragrisil;Gabriel Etienne

  • Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

    Michele Baccarani;Giuseppe Saglio;John Goldman;Andreas Hochhaus

  • Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

    Michele Baccarani;Jorge Cortes;Fabrizio Pane;Dietger Niederwieser

  • Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia

    Tim P. Hughes;Jaspal Kaeda;Susan Branford;Zbigniew Rudzki

  • Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia

    K. G. Roberts;Y. Li;D. Payne-Turner;R. C. Harvey

  • A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

    Jorge E. Cortes;D. W. Kim;J. Pinilla-Ibarz;P. Le Coutre

  • BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros

    Charles G. Mullighan;Christopher B. Miller;Ina Radtke;Letha A. Phillips

  • European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

    Andreas Hochhaus;Michele Baccarani;Richard T. Silver;Charles A. Schiffer

  • Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

    Andreas Hochhaus;Richard A. Larson;François Guilhot;Jerald P. Radich

  • Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.

    A. Hochhaus;S. G. O'Brien;F. Guilhot;B. J. Druker

  • Dynamics of chronic myeloid leukaemia.

    Franziska Michor;Timothy P. Hughes;Yoh Iwasa;Susan Branford

  • Lin28 promotes transformation and is associated with advanced human malignancies

    Srinivas R Viswanathan;John T Powers;William Einhorn;Yujin Hoshida

  • Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.

    A. Hochhaus;G. Saglio;Timothy Hughes;R. A. Larson

  • Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

    David M. Ross;Susan Branford;John F. Seymour;Anthony P. Schwarer

  • Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

    Andreas Hochhaus;Hagop M. Kantarjian;Michele Baccarani;Jeffrey H. Lipton

  • Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

    R. A. Larson;A. Hochhaus;T. P. Hughes;R. E. Clark

  • Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.

    Hagop M Kantarjian;Ricardo Pasquini;Nelson Hamerschlak;Philippe Rousselot

Frequent Co-Authors

Andreas Hochhaus
Andreas Hochhaus Friedrich Schiller University Jena
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Jorge E. Cortes
Jorge E. Cortes Augusta University
Giuseppe Saglio
Giuseppe Saglio University of Turin
Michele Baccarani
Michele Baccarani University of Bologna
Jerald P. Radich
Jerald P. Radich Fred Hutchinson Cancer Research Center
Neil P. Shah
Neil P. Shah University of California, San Francisco
Francois Guilhot
Francois Guilhot Grenoble Alpes University
Michael W. Deininger
Michael W. Deininger University of Utah
Richard A. Larson
Richard A. Larson University of Chicago

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a medical career in the USA doesn’t always mean committing to a lengthy, traditional MD route. There are several related online degrees and fast-track programs that can open doors in healthcare, offering flexibility and diverse career options.

For practicing nurses wanting to level up, you may consider exploring easy dnp programs online for a Doctor of Nursing Practice degree. These programs are designed to be accessible for working professionals seeking to enhance leadership in clinical practice.

If you’re just starting out, fast track lpn programs online allow students to quickly qualify as Licensed Practical Nurses, making it possible to begin a healthcare career in less than a year in many cases.

Those interested in mental health can benefit from psychiatric np programs for an MSN degree, helping meet the rising demand for advanced practice psychiatric nurses.

Alternatively, for students focused on the business side of healthcare, finding an affordable healthcare administration degree online can lead to roles managing hospitals, clinics, or healthcare organizations.

Best Scientists Citing Timothy P. Hughes

Trending Scientists